Psilocybin for Treatment of OCD-2

This randomised, double-masked Phase I/II trial (n=20) will study the safety, tolerability, and efficacy of psilocybin (10mg vs 30mg) across four sessions for the treatment of obsessive-compulsive disorder (OCD).

Led by Dr Francisco Moreno at the University of Arizona, this 12-week study will recruit 20 adults with moderate to severe OCD who are not currently using psychiatric medications.

Participants will be randomly assigned to receive either a low (10mg) or high (30mg) oral dose of psilocybin during four sessions, spaced three weeks apart. The study will assess changes in OCD severity, overall functioning, and quality of life using clinical scales such as the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Additionally, brain imaging (fMRI) and EEG will be used to explore neurological mechanisms of psilocybin’s effects. The trial also aims to examine whether the altered states of consciousness induced by psilocybin play a role in therapeutic outcomes. Safety precautions are in place due to psilocybin’s potential to induce intense psychological experiences, particularly at the higher dose. This trial hopes to lay the groundwork for a larger-scale study by identifying effective and tolerable dosing strategies.

Topic Obsessive-Compulsive Disorder Safety
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Arizona
Dr Franscio Moreno at the University of Arizona has been exploring the potential of psychedelic's to treat OCD.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.